Nucleic acid which encodes the tumor marker ZSIG62

Details Nucleic acid which encodes the tumor marker ZSIG62 Nucleic acid which encodes the tumor marker ZSIG62

2000-01-18

2002-06-11

Caputa, Anthony C. (Department: 1642)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C435S320100, C435S069100, C435S325000, C435S348000, C435S349000, C435S410000, C435S254100, C435S254200

Reexamination Certificate

active

06403783

ABSTRACT:

TECHNICAL FIELD
The present invention relates generally to a new polypeptide having diagnostic and therapeutic uses. In particular, the present invention relates to a novel tumor marker, designated “Zsig62,” and to nucleic acid molecules encoding Zsig62.
BACKGROUND OF THE INVENTION
Cancer is a complex disease, often having a mixed etiology. Although environmental factors appear to play a dominant role in the development of certain cancers, it is also clear that genetic factors determine cancer susceptibility (for a review, see Cornelisse and Devilee,
Patient Education and Counseling
32:9 (1997), Brandt-Rauf and Pincus,
Pharmacol. Ther.
77:135 (1998), and Jameson, “Oncogenes and Tumor Suppressor Genes,” in
Principles of Molecular Medicine,
Jameson (ed.), pages 73-82 (Humana Press, Inc. 1998)). Genetic changes can affect many aspects of cellular function, such as an increased rate of cellular proliferation, resistance to apoptosis, altered tissue invasiveness, production of growth and angiogenic factors, and the ability to avoid immune defenses.
For example, genetic alterations of oncogenes and tumor suppressor genes can be identified in a variety of human tumor tissues. Upon abnormal activation, the so-called “proto-oncogenes” can induce uncontrolled cellular proliferation. The products of proto-oncogenes include extracellular growth factors, transmembrane growth factor receptors, components of intracellular signal pathways, and components of the system that drives the cell division cycle and cellular self-destruction.
While proto-oncogenes are dominantly-acting genes, tumor suppressor genes act in a recessive manner. That is, both copies of a tumor suppressor gene must be inactivated to induce tumor growth. The inactivating mutations may be inherited in the germline, acquired by somatic mutation, or acquired by a combination of these events. The end result is that, when mutations inactivate both copies of tumor suppressor genes, normal inhibition of cellular growth is lost. Tumor suppressor genes include sequences that encode proteins involved in transcriptional regulation, cell cycle progression, and signaling pathways.
In certain cases, alterations in tumor suppressor genes are believed to occur early in the process of carcinogenesis and to be correlated with a subsequent development of cancer. The detection of such alterations would provide useful molecular markers for diagnosis, surveillance, early tumor identification and intervention, and prognosis. Yet the initial identification of a new tumor suppressor gene marker is difficult because mutations in these genes act recessively at the cellular level.
A need therefore exists for the identification of tumor suppressor genes that are involved in hereditary cancer syndromes.
BRIEF SUMMARY OF THE INVENTION
The present invention provides a novel gene, designated “Zsig62.” The present invention also provides Zsig62 polypeptides and Zsig62 fusion proteins, nucleic acid molecules encoding such polypeptides and proteins, and methods for using these amino acid and nucleotide sequences.


REFERENCES:
Alberts et al., Molecular Biology of the Cell, pp. 465, 1994.*
McClean et al., Eur. Journal of Cancer, vol. 29A, No. 16, pp 2243-2248, 1993.*
Fu et al., The EMBO Journal vol. 15. No. 16, pp 4392-4401, 1996.*
Shantz et al., The International Journal of Biochemistry & Cell Biology, vol. 31, pp. 107-122.*
Sequence from Incyte Pharmaceuticals, Inc., (No. INC4644734).
Sequence from Incyte Pharmaceuticals, Inc., (No. INC5272455).

Affiliated with

Also associated with

Rating

Nucleic acid which encodes the tumor marker ZSIG62 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acid which encodes the tumor marker ZSIG62, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid which encodes the tumor marker ZSIG62 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2895727